When combined with anti-PD-1 antibody immunotherapy, CDN-nanoparticles controlled B16-F1 melanoma tumor growth in vivo with a similar efficacy to a much higher dose (10×) of free CDN [175]. This evidence concerns the gene NT5C and neoplasm.